ALBUQUERQUE, N.M., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Biomoda, Inc. (OTCBB:BMOD), a diagnostics company focused on the development of accurate, inexpensive, and noninvasive in-vitro tests for the early detection of cancer, announced Dr. Thomas Bauer will read the follow-up CT scans and other data on study participants as part of the longitudinal component of the research of the Phase II clinical trial of its assay. Dr. Bauer is the Principal Investigator (PI) overseeing the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer.
